CHINT
1.6.2022 11:26:08 CEST | Business Wire | Press release
Hannover Messe in Germany, the global industrial technology "wind vane", was held from May 30 to June 2. CHINT, the world's leading provider of smart energy solutions, presented 10 products and solutions, which covered new energy, green and environmentally friendly smart transformers, and smart buildings, at the Energy Solutions Pavilion (H11.C30).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005678/en/
Centered around new energy and the entire industry chain, CHINT shared its practices and exploration in the fields of "green energy", "smart grid”, "load reduction" and “new energy storage”. “CHINT is about green development and the forefront of carbon emission reduction in the electricity and energy sector. After all these years, CHINT has accumulated and established a great number of top clients and a rich set of user scenarios to rapidly perceive and capture changes and new demands in markets and clients,” said Lily Zhang, CEO of CHINT Electrics.
In 2021, CHINT and BYD's energy storage project orders were successfully delivered, and these two partners joined together to serve the new energy market in the UK. During that year, CHINT's Saudi Arabia smart meter project delivered more than 500,000 smart circuit breakers to local areas. CHINT Cambodia developed off-grid photovoltaic systems in local areas, providing electricity to local areas using thousands of off-grid photovoltaic installations.
CHINT’s solutions are aimed at energy transformation to help bring about global climate objectives. At the exhibition, CHINT’s exhibit featured 8 events delivered in online/offline mode, sharing CHINT's new products and solutions. CHINT shared photovoltaic solutions by having their European team put on a show for the audience so they could experience CHINT’s new energy solutions and photovoltaic applications across large-scale ground, industrial, commercial and residential fields. This showcased the attraction of the innovative "photovoltaic +" model. CHINT also shared its CHINT Smart City energy-saving, low-carbon, interconnected and efficient solutions to the audience. Meanwhile, CHINT’s smart terminal molded case circuit breakers, Arc Fault Detection Devices (AFDD), and a number of new products took center stage, showcasing the company’s strengths in smart manufacturing.
Lily Zhang believes that “through a trade exhibition platform as important as Hannover, clients from more than 140 different nations and regions around the world have joined with CHINT to engage in discussions and exchanges. The cooperation formed between CHINT and international partners is full of endless potential and will leverage the CHINT’s global solution to boost green energy development.”
ABOUT CHINT GLOBAL
CHINT Global is committed to serving as the world's leading provider of intelligent energy solutions for the whole industrial chain. After more than 2 decades of global expansion, our business and marketing network covers over 140 countries and regions worldwide, with a wide range of industries in low voltage electric, smart electrics, energy instruments and meters, green energy, etc.
As the localization progresses steadily, through business integration and industrial upgrade, CHINT Global will further open up the supply chain, optimize the service system, and establish an ecological mechanism, in order to provide innovative integrated technological service for the global energy market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005678/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom